Topics
Pharmacology
What doctors should consider before prescribing e‐liquids for e‐cigarettes
In reply
Alexander Larcombe · David Chapman · Miranda Ween
Pharmacogenomics in the era of personalised medicine
Australia should develop a sustainable evidence-based pharmacogenomic screening program, with DPYD genotyping at the forefront
Cassandra White · Rodney Scott · Christine L Paul · Stephen P Ackland
Care for adults with COVID‐19: living guidelines from the National COVID‐19 Clinical Evidence Taskforce
Eight drug treatments are currently recommended for people who do not require supplemental oxygen and six for those who do
Heath White · Steve J McDonald · Bridget Barber · Joshua Davis · Lucy Burr · Priya Nair · Sutapa Mukherjee · Britta Tendal · Julian Elliott · Steven McGloughlin · Tari Turner
Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk
To the Editor: Khatri’s and Stuckey’s1 article, Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk, sums up the authors’ knowledge and experience of medication‐related osteonecrosis of the jaws (MRONJ) in the latter part of the title. They quote the risk of MRONJ as being very low and equal for denosumab and oral bisphosphonates. This is incorrect. The risk of MRONJ is 0.3%.2 In our study we found the risk following extractions at 1.8%.3 The recent 2022 update of the position paper on MRONJ4 found that the risk with denosumab is an order of magnitude higher than for bisphosphonates. There is no discussion in Khatri’s and Stuckey’s article1 of the effect of MRONJ on patients. A patient with stage 3 or end‐stage MRONJ has months of severe pain and requires jaw resection with or without microvascular reconstruction similar to that required for advanced jaw cancer.4,5 The impact of this is similar to vertebral collapse, both largely avoidable disasters. The current Australian recommendations for dental extractions for patients taking denosumab for osteoporosis are to delay extractions to 6 months after the last injection of denosumab and then to allow 4weeks for initial socket healing before the next injection.6 The risk is greater if the patient has been taking antiresorptives for more than 4years and if they are immunocompromised.4,7 We would agree that education and communication between prescribers, patients and dentists are key. This can only be achieved by close, mutually respectful communication and understanding between medical, dental, oral and maxillofacial surgeons and patients. However, this is easier to say than put into meaningful practice. Most definitive articles on MRONJ are in oral and maxillofacial surgery journals, which are not commonly read by physicians who prescribe antiresorptives. The most likely reason that the patient was taken off denosumab for 5 months was that the dental plan was not only to extract the teeth but to replace them with dental implants. Implants require time for osseointegration.8 Hopefully, this letter helps correct the distorted precepts expressed by Khatri and Stuckey for prescribers of this, otherwise, useful drug.
Alastair Goss
Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk
In reply
Bronwyn GA Stuckey · Nely Shrestha Khatri
Establishing the worth of deprescribing inappropriate medications: are we there yet?
The burden and costs of potentially inappropriate medications and polypharmacy are major public health challenges, but the effectiveness of deprescribing interventions in routine care remains unclear
Ian A Scott · Emily Reeve · Sarah N Hilmer
Primary headache drug treatment in emergency departments in Australia and New Zealand
Evidence-based guideline recommendations are not always followed in the ED
Kevin Chu · Anne‐Maree Kelly · Frances Kinnear · Gerben Keijzers · Sinan Kamona
Vaccine safety: what systems are required to ensure public confidence in vaccines?
No single surveillance system is perfect, but integrating data from multiple sources can provide comprehensive and reliable signal detection
Allen C Cheng · Jim P Buttery
More than a fleeting conversation: managing medication communication across transitions of care
Fostering engagement among older patients and families and creating opportunities for decision making about medications are crucial for improved safety and quality across transitions of care
Elizabeth Manias · Carmel Hughes · Robyn E Woodward‐Kron · Christine M Jorm · Guncag Ozavci · Tracey K Bucknall
Black hairy tongue: a spooky sign associated with penicillin therapy
A 21-year-old man noticed a blackish discoloration of the tongue at day 6 of oral penicillin intake following the extraction of retained molars
Dennis A Nowak · Benjamin E Nowak
Consensus statement on the current pharmacological prevention and management of heart failure
New recommendations for the pharmacological management of heart failure
Andrew P Sindone · Carmine De Pasquale · John Amerena · Christine Burdeniuk · Alicia Chan · Andrew Coats · David L Hare · Peter Macdonald · Aaron Sverdlov · John J Atherton
Review of management priorities for invasive infections in people who inject drugs: highlighting the need for patient‐centred multidisciplinary care
Using a multidisciplinary, pragmatic, patient-centred, non-judgemental approach may allow people who inject drugs to achieve improved outcomes for invasive infections and reduce their risk of subsequent admissions
Lucy O Attwood · Megan McKechnie · Olga Vujovic · Peter Higgs · Martyn Lloyd‐Jones · Joseph S Doyle · Andrew J Stewardson
The short term safety of COVID‐19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021
AusVaxSafety active surveillance affirms the short term safety of Comirnaty and Vaxzevria vaccines in a large population sample
Lucy Deng · Catherine Glover · Michael Dymock · Alexis Pillsbury · Julie A Marsh · Helen E Quinn · Alan Leeb · Patrick Cashman · Thomas L Snelling · Nicholas Wood · Kristine Macartney
Time to antithrombotic therapy after transient ischaemic attack and ischaemic stroke
Aspirin and other antithrombotics are proven to be effective in reducing ischaemic stroke recurrence
Thanh G Phan · Benjamin Clissold · Henry Ma
Drug‐induced anaphylaxis in Australia: we need a national drug allergy registry
A comprehensive adverse drug reaction registry with validated information would improve patient safety and care
Michaela Lucas · Sandra Vale
Emerging evidence for the use of colchicine for secondary prevention of coronary heart disease
Colchicine is an inexpensive new treatment for coronary heart disease that is both safe and effective in select patients
Stefan M Nidorf · Jamie Layland · Philip C Robinson · Sanjay Patel · Peter J Psaltis · Peter L Thompson
Long‐acting reversible contraception use after medical abortion is associated with reduced likelihood of a second medical abortion
Understanding of the benefits of early, reliable contraception after an abortion needs improving among health care practitioners and women
Luke E Grzeskowiak · Alice R Rumbold · Asvini Subasinghe · Danielle Mazza · Kirsten I Black · Helen Calabretto · Jenni Ilomäki
Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk
A 68-year-old woman presented for a medical consultation
Nely Shrestha Khatri · Bronwyn GA Stuckey
Medications that are unaccounted for in hospitals: discrepancies in electronic records
Reasons for inconsistencies need to be investigated to reduce the levels of medications that go missing
Valentina Lichtner
Australian consensus recommendations for the management of hepatitis B
This statement provides guidance to managing hepatitis B, recognising groups at increased risk of HBV infection and appropriate, timely screening strategies
John S Lubel · Simone I Strasser · Alexander J Thompson · Benjamin C Cowie · Jennifer MacLachlan · Nicole L Allard · Jacinta Holmes · William W Kemp · Avik Majumdar · David Iser · Jess Howell · Gail V Matthews
Does the FDA‐approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
Aducanumab, a controversial Alzheimer disease therapeutic with questionable efficacy, is under Therapeutic Goods Administration review
Andrew Gleason · Scott Ayton · Ashley I Bush
Efficacy, safety, and dose‐dependence of the analgesic effects of opioid therapy for people with osteoarthritis: systematic review and meta‐analysis
Opioid medications may provide very small benefits for people with osteoarthritis, but also increase the risk of adverse events
Christina Abdel Shaheed · Wasim Awal · Geoffrey Zhang · Stephen E Gilbert · Daniel Gallacher · Andrew McLachlan · Richard O Day · Giovanni E Ferreira · Caitlin MP Jones · Harbeer Ahedi · Mamata Tamrakar · Fiona M Blyth · Fiona Stanaway · Christopher G Maher
3D printing: potential clinical applications for personalised solid dose medications
Three- dimensional printing or additive manufacturing has the potential to transform personalised medicine
Liam Krueger · Jared A Miles · Kathryn J Steadman · Tushar Kumeria · Christopher R Freeman · Amirali Popat
COVID‐19 mRNA vaccine (Comirnaty)‐induced myocarditis
COVID-19 mRNA vaccine-related myocarditis is an extremely rare and mild complication, and is much less frequent than myocarditis secondary to COVID-19 infection
Joshua Wong · Sameer Sharma · Jessica V Yao · Anuradha Aggarwal · Leeanne Grigg
Medication not accounted for in hospital electronic medication administration records: a retrospective observational study
Almost 20% of units supplied to medical and surgical wards and emergency department were not administered to patients
Kimberly Walker · Andrew M Harding · Julina Tran · Paul Wembridge · Kent Garrett · Kent MacMillan · Olivia Rofe · Nicholas Jones · David Taylor